Visualising the world’s biggest pharmaceutical companies

‘Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. However, it’s likely no surprise that the pandemic has also been great for many healthcare businesses. In fact, in 2020 alone, the world’s 50 largest pharmaceutical companies still combined for a whopping $851 billion in revenues.

‘In this graphic, using data from Companies Market Cap, we list the largest pharmaceutical companies in the world by market capitalization. It’s worth noting this list also includes healthcare companies that work closely with pharmaceuticals, including biotech, pharmaceutical retailers, clinical laboratories, etc.’

Read here (Visual Capitalist, Sept 17, 2021)

The Bill Gates factor

‘Billionaire philanthropist Bill Gates has a key role in shaping the global response to the pandemic. And it’s not good news for health equality... 

‘A charitable take is that Gavi’s work, including Covax, bridges a gap – enabling the pharmaceuticals market to serve the needs of the poorest. But its model also props up that market, simultaneously bolstering an ideology of protection for intellectual property that socializes research and development risks but privatizes profits and control.

‘Intellectual property restrictions have created monopolies in both pharmaceuticals and software, crucial for the massive profits of Microsoft, where Gates made his billions. Meanwhile the Gates Foundation also has its own investments in Big Pharma, including Pfizer, and has funded organizations lobbying for industry-friendly regulations, such as the Drug Information Association and American Legislative Exchange Council.’

Read here (New Internationalist, April 26, 2021)

The race for antiviral drugs to beat Covid — and the next pandemic

‘Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing?...

“What we will hopefully find”, he [Alejandro Chavez, a bioengineer and antiviral drug researcher at Columbia University Irving Medical Center in New York City] says, “are inhibitors that work on, if you’re really lucky, an entire family.” That would make the best-case scenario a pan-coronavirus inhibitor. But a more reasonable goal might be developing a drug for a subset of coronaviruses, such as alphacoronaviruses, which currently cause non-lethal infections in humans, and having a different drug for betacoronaviruses, the group responsible for SARS, MERS, and COVID-19.

‘Once the viral lineage is identified, “the same principles of drug discovery apply”, says Marnix Van Loock, head of emerging pathogens at Johnson & Johnson’s global public-health unit in Beerse, Belgium. As he explains, researchers need to find ‘druggable pockets’ on the surface of essential enzymes that are conserved between related viruses and can be used to design active molecules.’

Read here (Nature, Apr 14, 2021)

From the pandemic, a roadmap for lowering the costs of medicine

‘To speed Covid-19 treatments, federal officials adopted a new, nimbler regulatory posture. The change was long overdue...

‘In recent decades, for example, the FDA — scarred by episodes like the Vioxx debacle and buoyed by scientists’ increased understanding of the body — has pressed drug makers to demonstrate increasingly rigorous understanding of the mechanisms by which their medicines work. Yet, one might argue that these guidelines reflect either hubris or naivete: The vast majority of safe and effective drugs were approved despite uncertainty about their mechanisms of action. Even today, scientists do not completely understand how acetaminophen works, yet the world is a far healthier place for having this drug...

‘In some high-profile cases during the pandemic, the FDA leaned less on mechanistic proof of effectiveness and more on empirical indicators, such as patient survival rates. For instance, when objective data revealed that the steroid dexamethasone helped severely ill patients survive what might otherwise have been deadly coronavirus infections, the FDA was quick to support the drug’s use, despite scientists having only a speculative understanding of how the steroid works against the disease. To be sure, the FDA must continue to prioritize its mandate to protect patients and clinical trial volunteers. But the pandemic has shown that safety and speed need not be an either-or proposition.’

Read here (Undark, Mar 25, 2021)

Greed is the problem, not the solution, for vaccine woes

‘On the anniversary of the United Kingdom’s first lockdown of the coronavirus pandemic, as candles were lit in doorways and the country mourned 125,000 deaths, the prime minister was in the mood for gloating. “The reason we have the vaccine success is because of capitalism, because of greed my friends,” Boris Johnson reportedly told Conservative MPs, before pleading “forget I said that”.

‘The AstraZeneca jab was actually developed by scientists from the University of Oxford, a publicly-funded institution, working with scientists from a range of backgrounds, including many educated in state schools. Those scientists had initially wanted to make their vaccine patent-free, before AstraZeneca entered the scene, effectively privatising the research.

‘The vaccines have been brought to market thanks to tens of thousands of trial volunteers who risked their health by putting themselves forward, not out of greed, but out of a desire to end this pandemic and help their families and communities. And the rollout is being managed by the UK’s National Health Service (NHS), a world-class public healthcare system that, despite market-driven reforms in recent years, exists entirely outside the logic of the market.

‘Greed, however, drove Big Pharma companies to privatise vaccines developed with public resources, and patent lifesaving medicines, in an effort to keep a grip on their monopolies. As a result, pharmaceutical giants sold these jabs almost exclusively to rich countries, allowing the UK to secure enough doses to vaccinate its population three times over.’

Read here (Aljazeera, Mar 24, 2021)

Strong support for TRIPS waiver amidst opposition by Big Pharma

‘More than 100 countries have upped the stakes for text-based negotiations on the TRIPS waiver proposal that seeks to temporarily suspend certain provisions of the WTO’s TRIPS Agreement in combating the COVID-19 pandemic, amidst attempts by Big Pharma to kill the waiver proposal, said people familiar with the development.

‘Ahead of the WTO’s TRIPS Council meeting on 10 March, the representatives of Big Pharma wrote to President Joseph Biden that the “US government has stood alongside other governments, including the European Union, United Kingdom, Japan, Canada, Switzerland, Brazil, and Norway to oppose this waiver.”

“We urge your administration to maintain this longstanding support for innovation and American jobs by continuing to oppose the TRIPS waiver,” said the CEOs of Pfizer, AstraZeneca, PhRMA (Pharmaceutical Research and Manufacturers of America), Eli Lilly, Bristol Myers Squibb, Gilead Sciences, Merck, Sanofi, Takeda Pharmaceuticals, Novartis, Abbvie, Bayer AG, Amgen Inc, and Biogen among others.

‘The CEOs of these companies, who constitute the powerful Big Pharma, decried the waiver proposal, saying that “in requesting the waiver, India and South Africa argued without evidence that the intellectual property is hindering the global response to the pandemic and that the waiver would help scale up research, development, manufacturing and supply of needed products.”

Read here (Third World Network, Mar 12, 2021)

Coronavirus and the money behind vaccines

The FT explains how the vaccine market works – including the cost of a vaccine and the vaccine development process – and the impact of the Covid-19 pandemic. This short documentary features global experts including Bill Gates, the CEOs of Moderna and Gavi, and the lead scientist behind the Oxford/AstraZeneca vaccine. 

View here (Financial Times, Youtube, Mar 10, 2021)

WTO DG meets Big Pharma and opts for voluntary licenses

‘The World Trade Organization Director-General Ms Ngozi Okonjo-Iweala said on 9 March that she fully supports the TRIPS waiver, insisting that she has conveyed to Big Pharma that they need to understand the “practicalities and sentiments” behind the demand for the waiver, said people familiar with the development.

‘Yet, she maintained that the TRIPS waiver may not be able to address the issue of ramping up production of vaccines to combat COVID-19 due to difficult manufacturing conditions that need to be complied with for producing vaccines, said people familiar with her remarks.

‘Her continued ambivalent positions seem to have undermined the move towards text-based negotiations on the TRIPS waiver, said people familiar with the development.’

Read here (Third World Network, Mar 10, 2021)

The antibody deception

‘Virtually every study and piece of marketing material related to Covid is premised on scientists having positively and correctly identified the presence of the novel coronavirus (also known as SARS-CoV-2) in the material they’re working with.

‘The job of that identification is usually given to antibodies that are said to bind to the novel coronavirus. The assumption is these antibodies are able to pick out the virus and only the virus from among every other organism and substance surrounding it.

‘Unfortunately it turns out that the antibodies rarely (if ever) do that. This is because of, among other things, inadequate verification of the antibodies’ accuracy in targeting the virus by the companies that manufacture and sell them. And there’s even less verification by government regulators.’

Read here (OffGuardian, Mar 6, 2021)

From Pfizer to Moderna: Who's making billions from Covid-19 vaccines?

‘Among the biggest winners will be Moderna and Pfizer – two very different US pharma firms which are both charging more than $30 per person for the protection of their two-dose vaccines. While Moderna was founded just 11 years ago, has never made a profit and employed just 830 staff pre-pandemic, Pfizer traces its roots back to 1849, made a net profit of $9.6bn last year and employs nearly 80,000 staff.

‘But other drugmakers, such as the British-Swedish AstraZeneca and the US pharma Johnson & Johnson, have pledged to provide their vaccines on a not-for-profit basis until the pandemic comes to an end.’

Also carried in this story are: Sinovac, Sputnik V, Novavax, CureVac 

Read here (The Guardian, Mar 6, 2021)

Fighting the medical monopoly: Mobilising for Zero-Covid and decommodified healthcare

‘As I have discussed in an article on Interferon 2b and Cuba’s other treatments for COVID-19, decommodified universal healthcare is the alternative to monopoly-driven healthcare ravaging countries around the globe. Not for profit production and delivery of all health related goods responding to general and specific human needs of the majority of any given country is the only means to assure quality health for all, in pandemic as well as non-pandemic times.

‘More concretely, decommodified universal healthcare is ecologically sound, public sector production of everything from food to psychological support, medicines to medical technology, and medical care. Rather than results based management and other corporate models adopted by most state owned enterprises globally in the past four decades, such public production would be designed and managed democratically by citizens, health professionals, scientists, and the range of other workers involved.

‘Taxation of corporations and rich individuals would be the primary means of financing decommodified universal healthcare. Due to the social importance of health related goods, and high employment potential given the extent of need in most countries around the globe, decommodified universal healthcare would constitute a significant segment of needs based, ecologically sound, nationally focused economies.’

Read here (The Bullet, Mar 4, 2021)

Countries urge drug companies to share vaccine know-how

‘Across Africa and Southeast Asia, governments and aid groups, as well as the World Health Organization, are calling on pharmaceutical companies to share their patent information more broadly to meet a yawning global shortfall in a pandemic that already has claimed over 2.5 million lives. Pharmaceutical companies that took taxpayer money from the U.S. or Europe to develop inoculations at unprecedented speed say they are negotiating contracts and exclusive licensing deals with producers on a case-by-case basis because they need to protect their intellectual property and ensure safety.’

Read here (AP, Mar 2, 2021)

Patently unfair: Can waivers help solve Covid vaccine inequality?

‘The World Trade Organization (WTO) General Council gathered virtually on Monday for the first of two days of talks amid increasing calls from civil society, states and nongovernmental actors to temporarily waive patents for COVID-19 vaccines and other coronavirus-related medical products. Endorsing a waiver on Friday, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said: “If not now, when?”

‘At the core of the discussion stands a proposal submitted in October by South Africa and India to suspend the WTO’s agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for the duration of the coronavirus pandemic. The goal is to facilitate the transfer of technology and scientific knowledge to developing countries to ramp up the global production of vaccines and other necessary equipment.’

Read here (Aljazeera, Mar 1, 2021)

Rich nations stockpiling a billion more COVID-19 shots than needed: Report

‘Rich countries are on course to have over a billion more doses of COVID-19 vaccines than they need, leaving poorer nations scrambling for leftover supplies as the world seeks to curb the coronavirus pandemic, a report by anti-poverty campaigners found on Friday. In an analysis of current supply deals for COVID-19 vaccines, the ONE Campaign said wealthy countries, such as the United States and Britain, should share the excess doses to “supercharge” a fully global response to the pandemic.

‘The advocacy group, which campaigns against poverty and preventable diseases, said a failure to do so would deny billions of people essential protection from the COVID-19-causing virus and likely prolong the pandemic. The report looked specifically at contracts with the five leading COVID-19 vaccine makers - Pfizer-BioNTech, Moderna, Oxford-AstraZeneca, Johnson & Johnson, and Novavax.’

Read here (Reuters, Feb 19, 2021)

Four principles for urgent pharma action to combat Covid-19

‘Collaboration is needed between pharmaceutical companies and governments to combat the spread of COVID-19 and accelerate access to tests, treatments and vaccines. Norway, which co-chairs the Facilitation Council of the ACT-Accelerator, is committed to ensuring the global vaccination effort is managed effectively. Here are four principles which could ensure equitable access to COVID-19 tools and health products, particularly for low and middle-income countries:

• Principle 1: File for registration rapidly, widely and on the basis of the most rigorous standards
• Principle 2: Price health technologies fairly
• Principle 3: Expand production and supply capacity
• Principle 4: Transparency

Read here (World Economic Forum, Feb 9, 2021)

Merck statement on ivermectin use during the Covid-19 pandemic

‘Merck, known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to-date, our analysis has identified:

• No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; 
• No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and; 
• A concerning lack of safety data in the majority of studies.

We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.

Read here (Merck press statement, Feb 4, 2021)

Bill Gates, Big Pharma and entrenching the vaccine apartheid

‘It appears that South Africa and India were right. Under the current rules, the vaccine cannot be made quickly or cheaply enough to meet global demand, which vaccines are only going to those countries that can afford it. This is a “catastrophic moral failure”, said the head of the World Health Organisation (WHO), Tedros Adhanom Ghebreyesus. Some activists have described the situation as a “vaccine apartheid”...

‘Nonetheless, the proposal for a patent waiver has been repeatedly rejected at the WTO by wealthier countries including the European Union, the United Kingdom, US and Switzerland; countries which, as Reuters wryly noted, are “all home to major pharmaceutical companies”. They also all enjoy early access to the vaccine.

‘Nor has South Africa and India’s proposal received support from the most influential non-state actor in global public health: Bill Gates...

‘But despite Gates’ stated commitment to an equitable distribution of the Covid vaccine, he is refusing to back South Africa and India’s calls for a waiver on patents... 

‘This should not come as a surprise: the Gates Foundation has historically been opposed to efforts to reform intellectual property protections for pharmaceutical companies — putting it at odds with other public health NGOs such as Doctors Without Borders (MSF) — and has in fact lobbied for developing countries to impose even stronger protections for drug companies’ patents. This is perhaps because Gates’ own fortune is built on intellectual property, specifically the copy­rights and patents associated with Windows and Microsoft.’

Read here (Mail&Guardian of South Africa, Jan 30, 2021)

Covid-19 vaccine developers ask the SEC to help keep the secret of how they set prices

‘When the U.S. government awarded over $10 billion in contracts and advance- purchase commitments to drug companies working on COVID-19 vaccine and treatments, it did not require the recipients of government money to agree to offer their products at fair prices or share intellectual property rights to enable faster production.

‘Now, two of the companies awarded those contracts—Pfizer and Johnson & Johnson—are trying to prevent shareholders from voting on resolutions to require the companies to disclose information about the impact of government funding on vaccine access...

‘The shareholder resolutions, filed by members of the Interfaith Center on Corporate Responsibility (ICCR), a shareholder activism organization, ask those two companies to inform their shareholders how "receipt of public financial support for development and manufacture of products for COVID-19 is being, or will be, taken into account when making decisions that affect access to such products, such as setting prices." Similar resolutions were also filed at Eli Lilly, Gilead, Merck, and Regeneron.

‘Both Pfizer and Johnson & Johnson filed "no action requests" with the Securities and Exchange Commission (SEC) in December, asking the agency to rule that the companies can withhold the proposals from shareholders. Neither company responded to The Daily Poster requests for comment.’

Read here (Newsweek, Jan 2, 2021)  

The vaccine news is great, but Big Pharma is still fooling us

‘Heroic work went into the development of the coronavirus vaccines. But that does not mean this industry deserves your affection...

‘I recall feeling, at the start of this pandemic, both horror at the unfolding calamity, and also a small sense of hope that as in other times of hardship, people would find ways to change the world for the better. There was talk of community support, mutual aid and the rediscovery of the positive powers of the state to protect its citizens. Much of that has dimmed now, and it often seems that we simply want relief - to go back to the way the world was before, and as soon as possible.

‘We have to get back to that place. Yet this may be the best chance in our lifetimes to break the hold of an industry that, until recently, was rightly vilified. The public is following these developments closely, and the state support that underwrites pharmaceutical profits couldn't be more obvious: Operation Warp Speed alone has dispensed over US$10 billion to the industry.

‘Pay it to make the vaccine, sure. That's a service. But we shouldn't be afraid to demand more: Public support should mean a public vaccine, one that reaches people as quickly as possible - profitable or not. The pharmaceutical industry wouldn't be able to rake in its profits and restore its reputation without funding that comes from our tax dollars. We shouldn't let Big Pharma forget it.’

Read here (Straits Times, Dec 22, 2020)

European Commission embarrassed by Covid-19 vaccine price leak

‘The tweeted information gave the following price per dose for each vaccine maker, in either euros or US dollars according to the respective contract:

1. AstraZeneca: €1.78
2. Johnson & Johnson: US$8.50
3. Sanofi/GlaxoSmithKline: €7.56
4. Pfizer/BioNTech: €12.00
5. Curevac: €10.00
6. Moderna: US$18.00’

Read here (Malay Mail, Dec 18, 2020)